- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00871052
Calcipotriol and Polymorphic Light Eruption
Calcipotriol in the Prevention of Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence, particularly among young women (up to 20%). The disease is characterized through itchy skin lesions on sun-exposed body sites occurring after sun exposure mostly in spring and early summer. Its etiopathogenesis is unknown but resistance to ultraviolet radiation (UVR)-induced immunosuppression with subsequent immune reactions against skin photoneoantigens has been suggested.
The phenomenon of UVR-induced immunosuppression (suppression of CHS) has been well known for many years. Recent findings showed that regulatory T cells (CD4+CD25+FoxP3+) (Tregs), a subset of T helper cells, are crucial in UVR-induced immunosuppression. However, the requirements for the maintenance of peripheral CD4+CD25+ T cells, important in suppression of immune responses, are still incompletely understood. Recent work suggests that cutaneous RANKL might be the physiologic missing link that couples UVR to immunosuppression. Epidermal RANKL, expressed in keratinocytes of inflamed skin due to e.g. UVR exposure was shown to control the number of Tregs via activation of dendritic cells, hereby mediating UVR-induced immunosuppression (e.g. suppression of allergic contact hypersensitivity responses). In addition to the suppression of local cutaneous hyperallergic responses, the development of systemic autoimmunity is suppressed. A strong inducer of RANKL expression and of Tregs is vitamin D3 that has been reported to have immunosuppressive effects. Interestingly, patients with autoimmune disorders (e.g. lupus erythematosus) may exhibit reduced vitamin D3 blood levels.
This randomized, double blinded left-right body side experimental comparison study was designed to assess the preventive effect of the vitamin D3 analogue calcipotriol in patients with PLE. The hypothesis is tested that treatment with a calcipotriol-containing cream can prevent the UVR-induced development of PLE skin lesions. Better insight into the pathogenesis of PLE may give clues to develop new therapeutic strategies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PLE patients will be recruited through the Photodermatology Unit of the Department of Dermatology, Medical University of Graz, Austria. Eligible patients will be identified through diagnosis-related computer-assisted search in the electronic patient chart system of the Unit. The diagnosis of PLE will be verified by patient's history, clinical symptoms, histologic findings, laboratory studies and/or phototesting procedures.
A calcipotriol-cream and a placebo cream are used in this study. Fifteen PLE patients will be enrolled. On day 1, the individual minimal erythema dose (MED) is assessed on patients' skin by exposure to a test ladder of solar-simulated UVR produced by a xenon arc source (Oriel Corp. Darmstadt, Germany). From day 2 to 5, 0.5 individual MED exposures (increased by 0 to 30% per exposure, depending on the erythema response to a preceding dose) are given to a total of four 10-by-10 cm skin test fields on symmetrically located, individual PLE predilection sites on the trunk or extremities. These test fields are pretreated in a randomized and double-blinded fashion either with the calcipotriol cream or the placebo cream (twice a day) during 7 days before start of phototesting.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, A-8036
- Medical University, Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of PLE either by typical history and/or typical histology of lesions and/or positive phototesting results
- Age > 18 years
Exclusion Criteria:
- Presence of or history of malignant skin tumors
- Dysplastic melanocytic nevus syndrome
- Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others
- Autoimmune disorders such as Lupus erythematosus or dermatomyositis
- Psychiatric disorders
- Immune deficiency or systemic treatment with steroids and/or other immunosuppressive drugs
- Pregnancy or lactation
- Antinuclear antibodies
- UV exposure in test fields within 8 weeks before study start
- General poor health status
- Severe liver or renal disease, disorders or therapy of the calcium metabolism with vitamin D containing drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Polymorphic light eruption score
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pruritus
Time Frame: 2 weeks
|
2 weeks
|
Erythema
Time Frame: 2 weeks
|
2 weeks
|
Tanning
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Graz IRB 19-129 ex 07/08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polymorphic Light Eruption
-
Clinuvel Pharmaceuticals LimitedCompletedPolymorphic Light Eruption (PLE)Austria, Australia, United Kingdom
-
Clinuvel Pharmaceuticals LimitedCompletedPolymorphic Light Eruption
-
Medical University of GrazRecruiting
-
Medical University of GrazAustrian Science Fund (FWF)TerminatedPolymorphic Light EruptionAustria
-
Medical University of GrazCompletedPolymorphic Light EruptionAustria
-
Centre de Pharmacologie Clinique Applique a la...CompletedPolymorphic Light EruptionFrance
-
Medical University of GrazCompletedPsoriasis | Atopic Eczema | Polymorphic Light EruptionAustria
-
Wake Forest University Health SciencesRecruiting
-
University Hospital, Strasbourg, FranceNot yet recruiting
-
Universidade Federal de AlfenasCompletedTooth Eruption DisorderBrazil
Clinical Trials on Calcipotriol-containing cream
-
LEO PharmaCompletedPsoriasis VulgarisCanada
-
West German Center of Diabetes and HealthBionatural GmbHCompleted
-
LEO PharmaCompletedAtopic DermatitisUnited Kingdom, Finland, Canada, Denmark
-
Chulalongkorn UniversityNot yet recruiting
-
The Catholic University of KoreaUnknownDrug-Related Side Effects and Adverse Reactions | Epidermal Growth FactorKorea, Republic of
-
The Catholic University of KoreaUnknownDrug-Related Side Effects and Adverse Reactions | Epidermal Growth FactorKorea, Republic of
-
NeoStrata Company, Inc.CompletedChronic Plaque PsoriasisUnited States
-
Chulalongkorn UniversityUnknown
-
Bitop AGCompletedMild to Moderate Atopic DermatitisGermany